Biomarkers for predicting intensive care unit stay duration for mechanically ventilated covid-19 patients
AssigneeQatar University
InventorsMohamed Elrayess, Asmaa Al-Thani, Hadi Yassine
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods that facilitate disease management by providing for early detection of metabolic changes that differentiate critically ill-COVID-19 patients under mechanical ventilation at the intensive care unit (ICU) who are likely to exhibit faster recovery.
Claims10
A method for predicting the length of stay (LOS) in an intensive care unit (ICU) for a patient under invasive mechanical ventilation (IMV) and who has COVID-19, or for assessing the risk of a long stay in the ICU for a patient under invasive mechanical ventilation (IMV), the method comprising:
- determining the expression level of at least one metabolite in an isolated biological sample at a first time point, wherein the at least one metabolite is selected from the group consisting of hypoxanthine and betaine, and
- determining whether the at least one metabolite is differentially expressed compared to a reference sample, wherein differential expression of the at least one metabolite is an upregulation or a downregulation,
- wherein differential expression of the metabolite predicts the length of stay for the patient, and
- treating the patient predicted to have a long stay in the ICU or having elevated risk of a long stay in the ICU, with a compound or other therapy to improve the prognosis for the patient and reduce the length of stay.
A method for predicting the duration of invasive mechanical ventilation (IMV) for a patient who has COVID-19, the method comprising:
- determining the expression level of at least one metabolite in an isolated biological sample at a first time point, wherein the at least one metabolite is selected from the group consisting of kynurenine, 3-methylhistidine, ornithine, p-cresol sulfate, and C24.0 sphingomyelin, and
- determining whether the at least one metabolite is differentially expressed compared to a reference sample, wherein differential expression of the at least one metabolite is an upregulation or a downregulation,
- wherein differential expression of the metabolite predicts the duration of IMV for the patient, and
- treating the patient to reduce the predicted duration of IMV, with a compound or other therapy to improve the prognosis for the patient and reduce the length of stay.
Dependencies are inferred from the claim text.